Abstracts tagged "Biologic drugs"

Abstract Number: 1511 • 2019 ACR/ARP Annual Meeting
Drug Survival of Ustekinumab in Psoriatic Arthritis: A Real-World Multicentric Cohort of 252 Patients
Jean-Guillaume Letarouilly¹, Benoit Flachaire ², Céline Labadie ³, Jérémie Sellam ⁴, Pascal Richette ⁵, Philippe Dieudé ⁶, Pascal Claudepierre ⁷, Bruno Fautrel ⁸, Eric Houvenagel ⁹, Chi Duc Nguyen ¹⁰, Marie-Hélène Guyot ¹¹, Nicolas Segaud ¹², Frédéric Maury ¹³, Laurent Marguerie ¹⁴, Xavier Deprez ¹⁵, Jean-Hugues Salmon ¹⁶, Guy Baudens ¹⁷, Elisabeth Gervais ¹⁸, Isabelle Chary-Valckenaere ¹⁹, Pierre Lafforgue ²⁰, Damien Loeuille ²¹, Christophe Richez ²², Thao Pham ²⁰ and René-Marc Flipo ²³, ¹University of Lille, CHU Lille, department of rheumatology, 59,000 Lille, France, Lille, Nord-Pas-de-Calais, France, ²Aix-Marseille University, CHU Marseille, department of Rheumatology, 13,000 Marseille, France, Marseille, Provence-Alpes-Cote d'Azur, France, ³Bordeaux University, CHU Bordeaux, department of Rheumatology, 33,000 Bordeaux, France, Bordeaux, Aquitaine, France, ⁴Service de Rhumatologie, AP-HP Hôpital Saint-Antoine, Sorbonne Université, INSERM, Centre de Recherche Saint-Antoine, Paris, France, Paris, France, ⁵Department of Rheumatology, AP-HP Lariboisiere Hospital, Paris, France, ⁶Rheumatology, Bichat Hospital, APHP, Paris;, Paris, France, ⁷Rheumatology, CHU Henri Mondor Créteil, Paris, France, ⁸Pitié-Salpêtrière Hospital, Department of Rheumatology, AP-HP, Sorbonne University, UPMC university, Paris, Ile-de-France, France, ⁹Rheumatology, Saint Philibert Hospital, Lille Cathololic Institute, Lomme, Lomme, France, ¹⁰Rheumatology, Hospital of Béthune, Béthune, Béthune, France, ¹¹Rheumatology, Hospital of Roubaix, Roubaix, Roubaix, France, ¹²Internal Medicine, Hospital of Armentières, Armentières, Armentières, France, ¹³Rheumatology, Private Practice, Beuvry, Beuvry, France, ¹⁴Rheumatology, Calot Institute, Berck, Berck-sur-Mer, ¹⁵Rheumatology, Hospital of Valenciennes, Valenciennes, Valenciennes, France, ¹⁶Rheumatology, Reims University Hospital, Reims, Reims, France, ¹⁷Rheumatology, Private Practice, Valenciennes, Valenciennes, France, ¹⁸CHU de Poitiers, Rheumatology, Poitiers, France, ¹⁹Centre Hospitalier Universitaire de Nancy, VANDOEUVRE, France, ²⁰Aix-Marseille University, CHU Marseille, department of Rheumatology, 13,000 Marseille, France, Marseille, France, ²¹Rheumatology, Nancy University Hospital and and UMR 7365 CNRS-UL IMoPA, Université de Lorraine, VANDOEUVRE, France, ²²Pellegrin Hospital, University Hospital of Bordeaux, Bordeaux, France, ²³University of Lille, CHU Lille, department of rheumatology, 59,000 Lille, France, Lille, France
Background/Purpose: Ustekinumab (UST) is a new biological Disease-modifying AntiRheumatic Drug (bDMARD) available in psoriatic arthritis (PsA), targeting respectively IL12-23. Real-world data are missing for this…
Abstract Number: 1529 • 2019 ACR/ARP Annual Meeting
The Efficacy and Safety of Anti-TNFα Treatment in Ankylosing Spondylitis Patients with Late Onset Compared to Those with Adult Onset; The Data from TURKBIO Registry
Sadettin Uslu¹, Gercek Can ², Ayşe Cefle ³, Sema Yılmaz ⁴, Sinem Burcu Kocaer ⁵, Tuba Yüce İnel ¹, Semih Gülle ¹, Süleyman Serdar Koca ⁶, Servet Yolbaş ⁷, Mehmet Akif Öztürk ⁸, Soner Senel ⁹, Nevsun Inanc ¹⁰, Ediz Dalkılıç ¹¹, Ozgül Gunduz ¹², Abdurrahman Tufan ⁸, Servet Akar ¹³, Merih Birlik ⁵, Ismail Sari ¹, Nurullah Akkoç ¹² and Fatos Onen ¹⁴, ¹Division of Rheumatology, Dokuz Eylül University School of Medicine, İzmir, Turkey, Izmir, Turkey, ²Dokuz Eylul University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Izmir, Izmir, Turkey, ³Division of Rheumatology, Kocaeli University School of Medicine, Kocaeli, Turkey, Kocaeli, Turkey, ⁴Division of Rheumatology, Selcuk University School of Medicine, Konya, Turkey, Konya, Turkey, ⁵Division of Rheumatology, Dokuz Eylül University School of Medicine, İzmir, Turkey, Turkey,Izmir, Izmir, Turkey, ⁶Fırat University School of Medicine Division of Rheumatology, Elazığ, Turkey, ⁷Division of Rheumatology, Inonu University School of Medicine, Malatya, Turkey, Malatya, Turkey, ⁸Division of Rheumatology, Gazi University School of Medicine, Ankara, Turkey, Ankara, Turkey, ⁹Division of Rheumatology, Erciyes University School of Medicine, Kayseri, Turkey, Kayseri, Turkey, ¹⁰Marmara University, Faculty of Medicine, Division of Rheumatology, Istanbul, Turkey, ISTANBUL, Turkey, ¹¹Uludağ University, Bursa, Turkey, ¹²Division of Rheumatology, Celal Bayar University School of Medicine, Manisa, Turkey, Manisa, Turkey, ¹³Izmir Katip Celebi University, Faculty of Medicine, Division of Rheumatology, İzmir, Turkey, ¹⁴Dokuz Eylul University School of Medicine, Division of Rheumatology, İzmir, Turkey
Background/Purpose: The first symptoms of ankylosing spondylitis (AS) patients usually begin prior to 45 years, but can occur later in life. The purpose of this…
Abstract Number: 1901 • 2019 ACR/ARP Annual Meeting
Serious Infections in Offspring Exposed in Utero to Non-TNFi Biologics and Tofacitinib
Evelyne Vinet¹, Yvan St-Pierre ¹, Cristiano S. Moura ¹, Jeffrey Curtis ² and Sasha Bernatsky ³, ¹McGill University Health Centre, Montreal, QC, Canada, ²University of Alabama at Birmingham, Birmingham, AL, ³Research Institute of the McGill University Health Centre, Montreal, QC, Canada
Background/Purpose: During pregnancy, maternal circulating immunoglobulins G (IgG) are actively transported across the placenta through their Fc portion. Thus, TNFi and other biologics harbouring an Fc…
Abstract Number: 2111 • 2019 ACR/ARP Annual Meeting
Symptomatic Coccidioidomycosis Infections in Patients on Biologic Therapies
Alexander Peck¹, Ella Starobinska ², Gilbert Ortega ¹, Travis Maestas ¹, Jaclyn Leong ¹, Phan Saligrama ¹, Jawad Bilal ¹ and Dominick Sudano ³, ¹University of Arizona College of Medicine, Tucson, AZ, ²University of Arizona College of Medicine, Tucson, AL, ³Banner University Medical Center Tucson, Tucson
Background/Purpose: Studies have shown an increased risk of coccidioidomycosis infection in immunosuppressed patients. However, relationship of coccidioidomycosis infections with different immunosuppressive medication is not well…
Abstract Number: 2398 • 2019 ACR/ARP Annual Meeting
Prevalence of Anxiety and Depression in a Cohort of Patients with Rheumatic Diseases on Biological Infusions
Alexander Peck¹, Ella Starobinska ², Gilbert Ortega ¹, Jaclyn Leong ¹, Travis Maestas ¹, Phan Saligrama ¹, Jawad Bilal ¹ and Dominick Sudano ³, ¹University of Arizona College of Medicine, Tucson, AZ, ²University of Arizona College of Medicine, Tucson, AL, ³Banner University Medical Center Tucson, Tucson
Background/Purpose: Studies have shown an increased prevalence of psychologic disorders in rheumatic diseases, such as rheumatoid arthritis, systemic lupus erythematosus, and psoriatic arthritis, compared to…
Abstract Number: 2406 • 2019 ACR/ARP Annual Meeting
Hepatobiliary Events in >5000 Patients with Inflammatory Arthritis Treated with Biosimilar or Originator Etanercept in Routine Care, Results from the Danish Nationwide DANBIO Registry
Bente Glintborg ¹, Stylianos Georgiadis ², Mette Nørgaard ³, Frank Mehnert ³, Kathrine Lederballe Grøn ¹, Niels Steen Krogh ⁴ and Merete Lund Hetland¹, ¹DANBIO and Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre of Head and Orthopaedics, Rigshospitalet, Copenhagen, Denmark, ²DANBIO registry and Copenhagen Center for Arthritis Research, Centre for Rheumatology and Spine Diseases, Rigshospitalet, Copenhagen, Denmark, ³Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark, ⁴Zitelab / DANBIO, Copenhagen, Denmark
Background/Purpose: Marketing of biosimilar biological drugs may significantly reduce drug costs if comparable safety and efficacy of originator and the biosimilar can be documented. In…
Abstract Number: 205 • 2019 ACR/ARP Annual Meeting
Does a Mandatory Non-medical Switch from Originator to Biosimilar Etanercept Lead to Increase in Healthcare Use and Costs? A Danish Register-based Study of 1620 Patients with Inflammatory Arthritis
Bente Glintborg ¹, Rikke Ibsen ², Rebekka Elisabeth Qwist Bilbo ³, Merete Lund Hetland¹ and Jakob Kjellberg ³, ¹DANBIO and Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre of Head and Orthopaedics, Rigshospitalet, Copenhagen, Denmark, ²i2minds, Aarhus, Denmark, ³VIVE, The Danish Centre for Social Science Research, Copenhagen, Denmark
Background/Purpose: Marketing of cheaper biosimilar biological agents has created financial incentives for switching from the corresponding originator drugs (=non-medical switch). The economic benefit might potentially…
Abstract Number: 2464 • 2019 ACR/ARP Annual Meeting
Multidisciplinary Unit of Psoriatic Arthritis: Clinical Results
Clara Pérez-Velásquez¹, Oihane Ibarguengoitia-Barrena ², David Montero-Seisdedos ², Lucía Vega-Alvarez ², Carmen García-Gómez ¹, Eva Galindez-Agirregoikoa ³, Silvia Pérez-Barrio ⁴, María Esther Ruiz-Lucea ², Ignacio Torre-Salaberri ², Ana Rosa Intxaurbe-Pellejero ², Olaia Fernandez-Berrizbeitia ¹, Juan María Blanco-Madrigal ², Eduardo Cuende-Quintana ², Itziar Calvo-Zorrilla ², Iñigo Gorostiza-Hormaeche ⁵, Natalia Andrea Rivera-García ², María Jesus Allande-López-Linares ², Helena Ugarte-Zuazo ² and María García-Vivar ¹, ¹University Hospital of Basurto, Bilbao, Pais Vasco, Spain, ²Rheumatology Unit, Basurto University Hospital, Bilbao, Spain, Bilbao, Spain, ³Hospital de Basurto, Bilbao, Pais Vasco, Spain, ⁴University Hospital of Basurto, Dermatology Department, Bilbao, Pais Vasco, Spain, ⁵Investigation Unit, Basurto University Hospital, Bilbao, Spain, Bilbao, Spain
Background/Purpose: The multidisciplinary unit of psoriatic arthritis (PsA) are attractive to improve the early diagnosis and optimize the management of complex patients with PsA. There…
Abstract Number: 248 • 2019 ACR/ARP Annual Meeting
Adherence to Biologic Disease-modifying Anti-rheumatic Drugs (DMARDs) —a Comparison of Long-term Adherence Among Patients with Various Inflammatory Conditions by Primary Dispensing Channel
Caroline Swift ¹, Yvonne Viteri², Gail Bridges ³, Mary Dorholt ⁴ and Monal Kohli ⁵, ¹Express Scripts, St. Louis, MO, ²Accredo, Northvale, NJ, ³Accredo, Memphis, TN, ⁴Accredo, Maple Grove, MN, ⁵Express Scripts, Franklin Lakes, NJ
Background/Purpose: Medication adherence to biologic DMARDs has been associated with optimal clinical outcomes. Adherence varies with primary dispensing channel among rheumatoid arthritis patients. Prior studies…
Abstract Number: 2731 • 2019 ACR/ARP Annual Meeting
Decomposition Analysis of Spending and Price Trends for Biologic Anti-Rheumatic Drugs in Medicare and Medicaid
Natalie McCormick¹, Zachary Wallace ², Chana Sacks ³, John Hsu ⁴ and Hyon K. Choi ⁵, ¹Massachusetts General Hospital and Harvard Medical School, Boston, MA, ²Massachusetts General Hospital, Boston, ³Department of General Internal Medicine, Massachusetts General Hospital; Department of Medicine, Harvard Medical School, Boston, MA, ⁴Mongan Institute, Massachusetts General Hospital; Department of Health Care Policy, Harvard Medical School, Boston, MA, ⁵Massachusetts General Hospital, Boston, MA
Background/Purpose: Billions of public dollars are spent each year on biologic disease-modifying anti-rheumatic drugs (bDMARDs), but the drivers of bDMARD spending and per-patient cost increases…
Abstract Number: 276 • 2019 ACR/ARP Annual Meeting
Effectiveness of Screening by Nurse with Predetermined Questionnaire on Infections Before Administration of Intravenous Biologics in Patients with Rheumatoid Arthritis
Sayaka Furukawa¹, Sho Fukui ¹, Sakura Tamaki ², Tomoko Nakasone ³ and Masato Okada ⁴, ¹St.Luke's International Hospital, Chuo-ku, Tokyo, Japan, ²St. Luke's International Hospital, Chuo-ku, Japan, ³St. Luke's International Hospital, Chuo-ku, Tokyo, Japan, ⁴St. Luke's International Hospital, Tokyo, Japan
Background/Purpose: Biologics are widely used as treatment for rheumatoid arthritis (RA), and pre-administration screening of active infection is imperative for the safety use. There is…
Abstract Number: 2826 • 2019 ACR/ARP Annual Meeting
Risk of Serious Infections in Tofacitinib versus Other Biologic Drug Initiators in Patients with Rheumatoid Arthritis: A Multi-database Cohort Study
Ajinkya Pawar ¹, Rishi Desai ¹, Nileesa Gautam ¹ and Seoyoung C. Kim², ¹Brigham and Women's hospital, Boston, ²Brigham and Women’s Hospital and Harvard Medical School, Boston
Background/Purpose: It is well-known that biologic or targeted synthetic DMARDs increase the risk of serious infections (SIs), but few studies have directly compared the risk…
Abstract Number: 549 • 2019 ACR/ARP Annual Meeting
US Rheumatologists’ Beliefs and Knowledge About Biosimilars – an Ongoing Survey
Allan Gibofsky¹, Dorothy McCabe ² and Sam Badawi ², ¹Weill Cornell Medical College, New York, NY, ²Boehringer Ingelheim, Ridgefield, CT
Background/Purpose: A systematic review of survey literature from 2014-2018 found that clinicians in the US and Europe are cautious about biosimilar use (JMCP; 2019;25:102). We…
Abstract Number: 2911 • 2019 ACR/ARP Annual Meeting
A Randomised, Open Labelled Clinical Trial to Investigate Synovial Mechanisms Determining Response – Resistance to Rituximab versus Tocilizumab in Rheumatoid Arthritis Patients Failing TNF Inhibitor Therapy
Frances humby ¹, Maya H. Buch ², Patrick Durez ³, Myles Lewis ¹, Michele Bombardieri ¹, Hasan Rizvi ⁴, Stephen Kelly ⁴, Liliane Fosatti ¹, Rebecca Hands ¹, Giovanni Giorli ¹, Arti Mahto ¹, Carlomaurizio Montecucco ⁵, Bernard Lauwerys ⁶, Vasco Romao ⁷, Arthur Pratt ⁸, Serena Bugatti ⁹, Nora Ng ¹⁰, Felice Rivellese ¹, Pauline Ho ¹¹, Mattia Bellan ¹², Mattia Congia ¹³, Patrick Verschueren ¹⁴, Pier Paolo Sainaghi ¹², Nagui Gendi ¹⁵, Bhaskar Dasgupta ¹⁶, Alberto Cauli ¹⁷, Piero Reynolds ¹⁸, Juan Cañete ¹⁹, Robert J. Moots ²⁰, Peter Taylor ²¹, Christopher Edwards ²², John Isaacs ⁸, Peter Sasieni ²³, João Eurico Fonseca ²⁴, Ernest Choy ²⁵ and Costantino Pitzalis²⁶, ¹Queen Mary University of London, London, United Kingdom, ²University of Leeds & NIHR Leeds Biomedical Research Centre, Leeds, United Kingdom, ³Pôle de Recherche en Rhumatologie, Institut de Recherche Expérimentale et Clinique, UCL Saint-Luc, Brussels, Belgium, ⁴Barts Health NHS Trust, London, United Kingdom, ⁵Department of Rheumatology, IRCCS Policlinico S. Matteo Foundation, University of Pavia, Pavia, Italy, Pavia, Italy, ⁶University of Louvain, Louvain, Belgium, ⁷University of Lisbon, Lisbon, Portugal, ⁸University of Newcastle, Newcastle, United Kingdom, ⁹University of Pavia, Pavia, Italy, ¹⁰Guys and St Thomas NHS Trust, London, United Kingdom, ¹¹University of Manchester, Manchester, United Kingdom, ¹²University of Novara, Novara, Italy, ¹³University of Cagliari, Cagliari, Italy, ¹⁴University of Leuven, Leuven, Belgium, ¹⁵Basildon Hospital NHS Trust, Basildon, United Kingdom, ¹⁶Southend University Hospital, NHS Foundation Trust, Westcliff-on-Sea, United Kingdom, ¹⁷Rheumatology Unit, University Clinic AOU and University of Cagliari, Cagliari, Italy, ¹⁸Homerton University NHS Trust, London, United Kingdom, ¹⁹Rheumatology Department, Hospital Clínic and IDIBAPS,, Barcelona, Spain, ²⁰Institute of Ageing and Chronic Disease, Liverpool, United Kingdom, ²¹University of Oxford, Oxford, United Kingdom, ²²University of Southampton, Southampton, United Kingdom, ²³Kings College London, London, United Kingdom, ²⁴Rheumatology and Bone Diseases Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte; Unidade de Investigação em Reumatologia, Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa; Centro Académico de Medicina de Lisboa; Lisbon, Portugal., Lisbon, Portugal, ²⁵Cardiff University School of Medicine, Cardiff, United Kingdom, ²⁶Centre for Experimental Medicine & Rheumatology, Queen Mary University of London, London, United Kingdom
Background/Purpose: Although biologic therapies have transformed the outlook for rheumatoid arthritis (RA), the lack of a major treatment response in over 50% of patients, the…
Abstract Number: 824 • 2019 ACR/ARP Annual Meeting
Results from a Randomized Controlled Trial of the Safety of the Live Varicella Vaccine in TNF-Treated Patients
Jeffrey Curtis¹, S Louis Bridges ², Stacey S Cofield ², John Bassler ¹, Theresa Ford ³, Stephen Lindsey ⁴, Alan Kivitz ⁵, Ilhem Messaoudi ⁶, Kaleb Michaud ⁷, Joseph Huffstutter ⁸, Ted Mikuls ⁹, David Ridley ¹⁰, William Shergy ¹¹, Sarah Siegel ¹² and Kevin Winthrop ¹³, ¹University of Alabama at Birmingham, Birmingham, AL, ²University of Alabama at Birmingham, Birmingham, ³North Georgia Rheumatology Group, PC, Lawrenceville, GA, ⁴Ochsner Clinic Foundation, Baton Rouge, LA, ⁵Altoona Center for Clinical Research, Duncansville, PA, ⁶University of California Irvine, Irvine, CA, ⁷University of Nebraska Medical Center, Omaha, NE, ⁸Arthritis Associates, Hixon, TN, ⁹VA Nebraska-Western IA Health Care System & University of Nebraska Medical Center, Omaha, NE, ¹⁰St. Paul Rheumatology, Eagan, MN, ¹¹Rheumatology Associates of North Alabama, Huntsville, AL, ¹²Oregon Health Science University, Portland, OR, ¹³Oregon Health and Science University, Portland, OR
Background/Purpose: There has been minimal evaluation of the safety of live virus vaccines in patients receiving biologic therapies who may be immunocompromised. The Varicella Zoster…

1
2
3
…
14
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].